Compare Ishares Msci Spain ETF (EWP) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Organon & Co. Common Stock — how do they compare? Ishares Msci Spain ETF trades at $57.9 (market cap $2.31B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Ishares Msci Spain ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and Organon & Co. Common Stock for 0 Days on average.
| EWP | OGN | |
|---|---|---|
Market Cap | $2.31B | $3.62B |
Volume | 302,484 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $13.81 |
52-Week Low | $48.95 | $5.70 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $58.34, up 0.52% on the day, with a bearish technical signal driven by moving averages. The stock faces resistance at $59 and support at $58. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights European market resilience amid ECB rate hikes and energy-driven inflation pressures.
Outlook is cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on Spain's equity valuation appeal, but risks include eurozone economic sentiment slippage and sustained inflation. Investors should await updated financials for fundamental assessment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
